SOCKET GRAFT

For use when all 4 bony walls are intact after extraction

Socket Graft is a dual phase calcium phosphate based synthetic bone graft material designed to treat the extraction socket, retain alveolar bone, and resorb quickly and completely.

This product should be stored in the freezer until use.

This product contains no human or animal tissue.

Implant placement in 8 weeks with predictable results

This material regenerates bone while it completely resorbs and becomes replaced by your patient’s own bone. A healthier bone regeneration sequence allows for an implant to be placed sooner than if other bone grafts were used. Implant placement at 8 weeks can now be achieved with predictable results.

For the injectable version of this graft material, see Socket Graft Injectable

INSURANCE CODES

D7953 Bone Replacement Graft (Socket Graft)
4267 GTR-Non-Resorbable Membrane

Instructions For Use

  • Remove the graft material from the freezer when ready to apply, not allowing the material to thaw
  • Open the white pouch and dispense the clear package onto the surgical site
  • Cut the clear package and use the bone graft immediately
  • Debride the socket, apply the first frozen petal into the socket, allow a few seconds for it to begin to thaw in the socket
  • As the second petal is applied, the sequential petals will also thaw but remain malleable for packing
  • If the graft material becomes wet, apply a sterile gauze over the graft and pack firmly to dry and condense the material
  • Cutting the petals in half will facilitate placement when approaching the crest
  • After the socket is packed, use a dense PTFE with Oral Bond (dental adhesive) to cover the graft
  • Place Oral Bond on the sutures and margins of the membrane to create a hermetic seal
  • Remove the sutures in 2 weeks and the membrane in 1 month
  • As an alternative, please use our sutureless membrane technique using Oral Bond

Precautions

  • Do not mix with any other graft materials other than SteinerBio bone grafts
  • Do not use animal or human membranes to cover Socket Graft or the graft may fail

Our grafts are categorized by the FDA as both a medical device and a drug. The FDA has allowed SteinerBio to claim that these bone grafts stimulate osteogenesis.

Furthermore, our grafts are expressly cleared by the FDA for implant placement.

All compounds are synthesized ultra-pure, ensuring the process of bone growth is safe, predictable, and effective.

Strengthen Your Practice

Socket Graft will change your practice when your patients realize our technology is available to them. Your patients now have a choice between a chemically pure, FDA cleared bone graft or the frequently off-putting choice of cadaver tissue. Resorbable synthetics and autografts are the only bone grafts that produce normal bone. Normal bone is the only type of bone that has been shown to support an implant for a lifetime.

Socket Graft provides the organic and inorganic molecules a bone needs in order to regrow faster, stronger, healthier, and more vital. Our patented SL Factor in our bone graft material targets the osteoblasts within the patient’s bone, initiating the bone regeneration process. Our product has been classified as a drug device and this the drug contained in this product has been shown to stimulate bone formation.

How Does SL Factor Work?

SteinerBio has the only bone grafts on the market that contain a drug that changes the physiology of a bone’s osteoblasts to stimulate osteogenesis. SL Factor, our patented organic compound, enters through the membrane of the osteoblasts and results in the following metabolic activities:

  • SL Factor is absorbed by the osteoblasts
  • SL Factor activates over 300 genes that stimulate the process of bone formation
  • BMP2 and RUNX2 production increases two-fold and reduces osteoclast formation by inhibiting the production of RANK ligand
  • Osteocalcin accumulation is enhanced in the extracellular matrix resulting in excellent mineralization
  • While stored in the osteoblast, SL Factor continues to stimulate bone growth after the synthetic matrix has been resorbed
  • Adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression is inhibited
  • Inflammation is reduced by inhibiting prostaglandin synthesis

“Modern beta tricalcium phosphate bone grafts perform as well or better than allografts or autografts. The negatives of autograft morbidity and cadaver harvesting makes high performing βTCP a superior choice.”

MEMBER:

American Society for Bone and Mineral Research (ASBMR)

Tissue Engineering and Regenerative Medicine International Society (TERMIS)

American Academy of Implant Dentistry (AAID)